MedTrace Logo

Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer

NCT02967770 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-09-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether molecularly tailored therapy can improve the efficacy of treatment when compared to standard chemotherapy combinations for patients with metastatic pancreatic cancer receiving their second line of therapy for metastatic disease.

Conditions

Interventions

OTHER

Molecularly Tailored Second Line Therapy

This trial is designed to assess the efficacy of MTT vs. SOC therapy as second-line therapy in patients with metastatic pancreatic cancer.

DRUG

Standard of Care Second Line Therapy

Sponsors & Collaborators

  • Thomas Jefferson University

    collaborator OTHER

  • Sinai Health System

    collaborator OTHER

  • Virginia Mason Hospital/Medical Center

    collaborator OTHER

  • Cedars-Sinai Medical Center

    collaborator OTHER

  • George Mason University

    collaborator OTHER

  • Caris Life Sciences

    collaborator INDUSTRY

  • Theranostics Health, Inc

    collaborator UNKNOWN

  • Guardant Health, Inc.

    collaborator INDUSTRY

  • Companion Diagnostics, Inc.

    collaborator UNKNOWN

  • Georgetown University

    lead OTHER

Principal Investigators

  • Michael Pishvaian, MD, PhD · Georgetown Lombardi Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-08-30
Completion
2018-08-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02967770 on ClinicalTrials.gov